Biogen pays $75M upfront to Pfizer for a schizophrenia drug
Biogen has agreed to acquire a schizophrenia drug candidate from New York-based pharmaceutical giant Pfizer Inc.
The purchase allows Cambridge-based Biogen (Nasdaq: BIIB) to develop a new treatment for cognitive impairment.
“When cognition is impaired, you lose the ability to make sense of the world," said Michael Ehlers, executive vice president, Research& Development at Biogen. "Things we often take for granted in our daily lives, including processing information, planning and remembering, …
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Anthony Noto Source Type: news